Try our Advanced Search for more refined results
Life Sciences
-
January 16, 2026
6th Circ. Revives Biomed Co. Investor's Suit Over Stock Sale
The Sixth Circuit has ruled that a man who sold his stock in a biomedical research company just before being told the company planned to pursue private equity financing can bring his breach of contract and fiduciary duty claims, reversing a lower court's ruling granting summary judgment to the biomedical company.
-
January 16, 2026
NuVasive Loses Appeal Over Ex-Exec's Ties To Competitor
The Delaware Supreme Court on Friday affirmed the dismissal of NuVasive Inc.'s long-running lawsuit accusing a former top executive of breaching fiduciary duties and contractual obligations while planning to move to a rival spine-surgery company, ending nearly a decade of litigation over alleged conflicts and disloyal conduct.
-
January 16, 2026
Acadia Investors Get Initial OK For $179M Settlement
Acadia Healthcare Co. Inc. investors have received the first OK from a Tennessee federal judge for a $179 million settlement in a class action alleging the company misled them about the strength of its U.K. operations.
-
January 16, 2026
Pomerantz To Lead Biohaven Investors' FDA Approval Suit
Pomerantz LLP will lead a proposed class of investors accusing biopharmaceutical company Biohaven Ltd. of overstating the odds that two of its product candidates would receive regulatory approval, a Connecticut judge said Friday.
-
January 16, 2026
Taxation With Representation: Stibbe, A&O Shearman, Latham
In this week's Taxation With Representation, Keurig Dr Pepper Inc. plans to complete its deal to snap up coffee company JDE Peet's NV, Boston Scientific Corp. acquires medical device company Penumbra Inc., and fitness and wellness platform parent Playlist merges with fitness technology company EGYM.
-
January 16, 2026
J&J Largely Loses Bid To Toss Former Atty's NJ Bias Suit
A New Jersey federal judge largely shot down Johnson & Johnson's bid to scrap a former company data privacy attorney's racial and gender discrimination suit and rejected its bid to sanction her over the case.
-
January 16, 2026
Supreme Court Takes On Hikma's 'Skinny Label' Patent Case
The U.S. Supreme Court agreed Friday to hear Hikma Pharmaceuticals Inc.'s appeal of a decision reviving a patent case over its "skinny label" on a generic heart drug, after the Trump administration urged the court to take the case.
-
January 16, 2026
Bioness $110M Sale Suit Heads to $8.9M Deal
A Delaware Chancery Court class action challenging the $110 million sale of medical device maker Bioness Inc. to Bioventus Inc. is reaching a resolution through an $8.9 million proposed settlement, capping years of litigation over whether the deal was engineered to favor the company's controlling creditor at the expense of minority stockholders.
-
January 15, 2026
SEC Says Healthcare Exec Misspent $10.6M In Investor Funds
The U.S. Securities and Exchange Commission on Thursday accused a healthcare company CEO of misappropriating over $10 million from investors by falsely claiming the funds would be used to develop cancer screening and treatment technology when in fact they were spent on credit card debt, luxury vehicles and strip club visits.
-
January 15, 2026
Ex-CEO Of COVID Vax Maker Accused Of Insider Trading
New York Attorney General Letitia James on Thursday sued the former CEO of healthcare contractor Emergent BioSolutions Inc., alleging insider trading amid troubles manufacturing a COVID-19 vaccine, while signing a $900,000 settlement with the company over its approval of an executive trading plan.
-
January 15, 2026
Trial 'No Longer Warranted' After Judge's Stelara Reversal
The fate of insurer CareFirst's suit accusing Johnson & Johnson of using a merger and patent fraud to anticompetitively protect immunosuppressive drug Stelara from competition is in doubt after a Virginia federal judge reversed course and nixed key claims he had previously teed up for trial.
-
January 15, 2026
Simpson Thacher Guides New Mountain's $1.2B Fund Close
New Mountain Capital LLC, guided by Simpson Thacher & Bartlett LLP, has closed its second noncontrol private equity fund with $1.2 billion raised, aiming to use the funds to target companies in industries such as healthcare technology and life sciences, the alternative investment firm announced on Thursday.
-
January 15, 2026
Chancery Tosses Vividion IP Suit Over $2B Bayer Deal
The Delaware Chancery Court on Thursday dismissed a biotech investor's suit accusing the co-founder of Vividion Therapeutics Inc. and others of diverting valuable intellectual property ahead of the company's $2 billion sale to Bayer Corp., finding the alleged misconduct could not have affected the merger price or process under Delaware law.
-
January 15, 2026
CVS Ducks Antitrust But Not Biz Interference Claim At 5th Circ.
A Fifth Circuit panel has largely sided with CVS Pharmacy and its Caremark affiliate by preserving a district court's dismissal of federal antitrust claims over a Mississippi pharmacy's rejection from participating in the pharmacy benefit manager's network, although the judges did revive state law claims.
-
January 15, 2026
Rite Aid Trusts Can Access Health Data To Pursue Tort Claims
A New Jersey bankruptcy judge said Thursday he will allow trusts set up under Rite Aid's first Chapter 11 plan to examine personal health data to support their effort to litigate tort and insurance claims, overruling the new Rite Aid debtor's objection.
-
January 15, 2026
Crowell Lands Buchalter Practice Group Co-Chair In Calif.
Crowell & Moring LLP announced Thursday that it has added the former co-chair of Buchalter PC's white collar and government investigations practice to bolster its capacity to handle healthcare fraud and other cases.
-
January 15, 2026
White & Case Adds Life Sciences Team From A&O Shearman
White & Case LLP announced the addition of four life sciences intellectual property litigators from Allen Overy Shearman Sterling on Thursday, marking its latest IP-focused hires from the London-based firm.
-
January 15, 2026
Carlyle Among Bidders For Lukoil Assets, Plus More Rumors
Private equity giant Carlyle is among a group of bidders reportedly looking to grab hold of $22 billion worth of Russia's Lukoil assets; Canadian oil and gas company Canadian Natural Resources is looking to acquire Tourmaline Oil Corp.'s $1 billion portfolio of natural gas properties; and Nvidia rival Cerebras eyes a $22 billion valuation after a planned $1 billion funding round.
-
January 15, 2026
3 Firms Advise On Boston Scientific's $14.5B Penumbra Deal
Allen Overy Shearman Sterling and Arnold & Porter are advising Boston Scientific Corp. on an agreement announced Thursday for the global medical technology company to purchase Davis Polk-advised Penumbra Inc. at a $14.5 billion enterprise value.
-
January 14, 2026
Dover Launches RICO Suit Over Skyrocketing Insulin Prices
Manufacturing conglomerate Dover Corp. hit insulin manufacturers including Eli Lilly and Novo Nordisk and several pharmacy benefit managers with civil racketeering claims in Illinois federal court, accusing them of participating in an illegal scheme that allowed prices to rise dramatically in exchange for preferential treatment on the benefit managers' formularies.
-
January 14, 2026
Pharmacy Wields Antitrust Law In Challenge To GLP-1 Giants
Eli Lilly & Co. and Novo Nordisk are using their dominant positions in the market for weight loss and diabetes medications to squash potential competitors, including through unlawful exclusivity agreements with telehealth providers, a compounding pharmacy alleged Wednesday in what it calls a landmark antitrust lawsuit.
-
January 14, 2026
6th Circ. Skips Rethink, But Still Spars Over Indirect Buyer Bar
A decision by the full Sixth Circuit not to rehear a lawsuit over an alleged allergy testing and treatment provider boycott has turned into an internal dustup about the limits of who can seek damages under federal antitrust law, with one judge calling for U.S. Supreme Court intervention.
-
January 14, 2026
Exasperated Judge Won't Expand Opioid Film Injunction
BioDelivery Sciences International needed to pursue a contempt order, not an enforcement action, when alleging a 2022 injunction blocking Alvogen's generic version of its Belbuca opioid film should be applied to a new generic application, a Delaware federal judge held in a case where he was already "frustrated (and exhausted)."
-
January 14, 2026
NJ Judge Orders Mediation In Merck-Cencora Indemnity Fight
Cencora Inc. can't derail a Merck third-party complaint arguing a prior settlement between the parties requires the drug wholesaler to indemnify Merck in antitrust litigation by Humana, a New Jersey federal court ruled Wednesday, ordering the parties to go to mediation over the dispute.
-
January 14, 2026
Biotech Co. CytoDyn In Talks To End Investor Class Action
A federal judge has given the green light for biotech company CytoDyn Inc. and its former leadership to move forward with a potential settlement of a proposed class action that accused the company of misleading shareholders over the alleged approval of its COVID-19 and HIV drug.
Expert Analysis
-
IP Ownership Risk Grows In Booming Cancer Drug Market
The ownership of intellectual property has become strategically decisive in deals involving valuable cancer therapeutics known as ADCs, as highlighted by the recent Takeda-Innovent deal, with the commercial value of a license resting on the integrity and defensibility of the underlying technology, say attorneys at Loeb & Loeb.
-
Series
My Miniature Livestock Farm Makes Me A Better Lawyer
Raising miniature livestock on my farm, where I am fully present with the animals, is an almost meditative time that allows me to return to work invigorated, ready to juggle numerous responsibilities and motivated to tackle hard issues in new ways, says Ted Kobus at BakerHostetler.
-
Surveying The Healthcare Policy Landscape Post-Shutdown
With last week's agreement to reopen the federal government, at least through the end of January, key healthcare legislation that has been in limbo since a December 2024 spending bill fell apart may recapture the attention of Congress, say attorneys at Faegre Drinker.
-
FDA Biosimilar Guidance Should Ease Biologics Development
New draft guidance from the U.S. Food and Drug Administration, indicating that the agency may no longer routinely require comparative efficacy studies when other evidence provides sufficient assurance of biosimilarity, underscores the FDA's trust in analytical technology as a driver of biologics access, say attorneys at Hogan Lovells.
-
Litigation Funding Could Create Ethics Issues For Attorneys
A litigation investor’s recent complaint claiming a New York mass torts lawyer effectively ran a Ponzi scheme illustrates how litigation funding arrangements can subject attorneys to legal ethics dilemmas and potential liability, so engagement letters must have very clear terms, says Matthew Feinberg at Goldberg Segalla.
-
E-Discovery Quarterly: Recent Rulings On Dynamic Databases
Several recent federal court decisions illustrate how parties continue to grapple with the discovery of data in dynamic databases, so counsel involved in these disputes must consider how structured data should be produced consistent with the requirements of the Federal Rules of Civil Procedure, say attorneys at Sidley.
-
How Litigating Antitrust Fix Helped GTCR Prevail In Court
An Illinois federal judge's recent denial of the Federal Trade Commission's injunction request in the GTCR acquisition of Surmodics joins a developing series of cases in which deal parties have prevailed against government antitrust challenges by proposing a post-complaint fix and litigating the as-amended deal, say attorneys at Paul Weiss.
-
Series
Building With Lego Makes Me A Better Lawyer
Building with Lego has taught me to follow directions and adapt to unexpected challenges, and in pairing discipline with imagination, allows me to stay grounded while finding new ways to make complex deals come together, says Paul Levin at Venable.
-
The Rise Of Trade Secret Specificity As A Jury Question
Recent federal appellate court decisions have clarified that determining sufficient particularity under the Defend Trade Secrets Act is a question of fact and will likely become a standard jury question, highlighting the need for appropriate jury instructions that explicitly address the issue, says Amy Candido at Simpson Thacher.
-
Series
Law School's Missed Lessons: Networking 101
Cultivating a network isn't part of the law school curriculum, but learning the soft skills needed to do so may be the key to establishing a solid professional reputation, nurturing client relationships and building business, says Sharon Crane at Practising Law Institute.
-
Defeating Estoppel-Based Claims In Legal Malpractice Actions
State supreme court cases from recent years have addressed whether positions taken by attorneys in an underlying lawsuit can be used against them in a subsequent legal malpractice action, providing a foundation to defeat ex-clients’ estoppel claims, says Christopher Blazejewski at Sherin and Lodgen.
-
Trade Secret Rulings Reveal The Cost Of Poor Preparation
Two recent federal appellate decisions show that companies must be prepared to prove their trade secrets with specificity, highlighting how an asset management program that identifies key confidential information before litigation arises can provide the clarity and documentation that courts increasingly require, say attorneys at Mintz.
-
Series
The Biz Court Digest: How It Works In Massachusetts
Since its founding in 2000, the Massachusetts Business Litigation Session's expertise, procedural flexibility and litigant-friendly case management practices have contributed to the development of a robust body of commercial jurisprudence, say James Donnelly at Mirick O’Connell, Felicia Ellsworth at WilmerHale and Lisa Wood at Foley Hoag.
-
Why Appellees Should Write Their Answering Brief First
Though counterintuitive, appellees should consider writing their answering briefs before they’ve ever seen their opponent’s opening brief, as this practice confers numerous benefits related to argument structure, time pressures and workflow, says Joshua Sohn at the U.S. Department of Justice.
-
Navigating DEA Quotas: Key To Psychedelics Industry Growth
As new compounds like DOI enter the Schedule I landscape, manufacturers who anticipate U.S. Drug Enforcement Administration quota regulations, and build quota management into their broader strategy, will be best equipped to meet the growing demand, say Kimberly Chew at Husch Blackwell and Jaime Dwight at Promega.